Drug Approval | July 18, 2022
Orchid Pharma updates on PLI scheme benefits for its subsidiary
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
This acquisition is in line with Cipla's strategic imperative to augment the company's wellness portfolio for bringing about a shift from an illness to a wellness mindset.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Site Enhances New Modality CRDMO Platform Capacity for Customers
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
Subscribe To Our Newsletter & Stay Updated
